289 related articles for article (PubMed ID: 8706593)
1. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.
Rosen CJ; Kessenich CR
Drugs; 1996 Apr; 51(4):537-51. PubMed ID: 8706593
[TBL] [Abstract][Full Text] [Related]
2. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
Chapurlat R; Meunier PJ
Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
[TBL] [Abstract][Full Text] [Related]
3. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.
Reginster JY
Bone; 1992; 13(5):351-4. PubMed ID: 1419375
[No Abstract] [Full Text] [Related]
4. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
Cremers S; Garnero P
Drugs; 2006; 66(16):2031-58. PubMed ID: 17112299
[TBL] [Abstract][Full Text] [Related]
5. Alendronate reaches U.S. market for osteoporosis, Paget's disease.
Am J Health Syst Pharm; 1995 Nov; 52(22):2513-4. PubMed ID: 8590234
[No Abstract] [Full Text] [Related]
6. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
[TBL] [Abstract][Full Text] [Related]
7. Treatment of osteoporosis and Paget's disease.
Stewart GO; Nicholson GC
Curr Opin Rheumatol; 1991 Jun; 3(3):380-7. PubMed ID: 1883692
[TBL] [Abstract][Full Text] [Related]
8. [Use of bisphosphates in treatment of primary and secondary osteoporosis].
Olszyński WP
Pol Tyg Lek; 1995 Nov; 50(44-47):56-8. PubMed ID: 8643431
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of Paget's disease].
Kurth AA
Orthopade; 2007 Feb; 36(2):118, 120-3. PubMed ID: 17252256
[TBL] [Abstract][Full Text] [Related]
10. Risedronate: clinical usage.
Chapurlat RD; Delmas PD
Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
[TBL] [Abstract][Full Text] [Related]
11. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate use in conditions other than osteoporosis.
Silverman SL
Ann N Y Acad Sci; 2011 Feb; 1218():33-7. PubMed ID: 20946575
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Paget's disease of bone with bisphosphonates.
Mazières B
Rev Rhum Engl Ed; 1995 Feb; 62(2):72-8. PubMed ID: 7600075
[No Abstract] [Full Text] [Related]
14. The therapeutic use of bisphosphonates.
Compston JE
BMJ; 1994 Sep; 309(6956):711-5. PubMed ID: 7950525
[No Abstract] [Full Text] [Related]
15. [Questions and answers about bisphosphonates].
Letonturier P
Presse Med; 2007 Mar; 36(3 Pt 1):440. PubMed ID: 17436449
[No Abstract] [Full Text] [Related]
16. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Dunn CJ; Goa KL
Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology and therapeutic utility of bisphosphonates.
Lourwood DL
Pharmacotherapy; 1998; 18(4):779-89. PubMed ID: 9692651
[TBL] [Abstract][Full Text] [Related]
18. Ibandronate.
Dooley M; Balfour JA
Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in the treatment of metabolic bone diseases.
Rodan GA; Balena R
Ann Med; 1993 Aug; 25(4):373-8. PubMed ID: 8217103
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates: an overview with special reference to alendronate.
Vasikaran SD
Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
